1-3 of 3
V. Michael Holers, MD
Close
Sort by
Journal Articles

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, Nirmal K Banda, PhD, V. Michael Holers, MD, Akshay Vaishnaw, MD PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Klaus Charisse, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, David J Salant, MD, Kevin Fitzgerald, PhD, Rachel Meyers, PhD, Benny Sorensen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1606.
https://doi.org/10.1182/blood.V124.21.1606.1606
Published: 2014
Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD
Journal: Blood
Blood (2010) 116 (21): 637.
https://doi.org/10.1182/blood.V116.21.637.637
Published: 2010
Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD
Journal: Blood
Blood (2010) 116 (21): 638.
https://doi.org/10.1182/blood.V116.21.638.638
Published: 2010